Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGc-0201 plus Tislelizumab in High-Risk HCC
NCT07077369Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Phase 1, open-label trial of WGc-0201 in hepatocellular carcinoma (HCC) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose limiting toxicity at 1 year. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
WGc-0201
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07077369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077369.